|
|
|
|
|
Product Name
|
NQO1 antibody
|
| |
See all NQO1 antibodies (9)...
|
|
Product type
|
Primary antibodies
|
|
Description
|
Rabbit polyclonal to NQO1
|
|
Immunogen
|
Synthetic peptide derived from the N terminal domain of human NQO1
|
|
Reacts with
|
Hu
|
|
Predicted to react
(species key)
|
Ms, Rat (Due to sequence homology)
|
|
Specificity
|
ab75342 reacts specifically with NQO1.
|
|
Tested applications
(see key)
|
IHC-P, WB
|
|
|
Abreviews
|
|
|
|
Application notes
(see key)
|
Recommended dilutions IHC-P: Use at an assay dependent dilution. WB: 1/200 - 1/2000. Predicted molecular weight: 31 kDa.
Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.
|
|
Cellular localization
|
Cytoplasmic
|
|
Research areas
|
Signal Transduction >> Metabolism >> Drug metabolism
|
|
Relevance
|
NQO1 is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a cytoplasmic 2-electron reductase. This FAD-binding protein forms homodimers and reduces quinones to hydroquinones. NQO1's enzymatic activity prevents the one electron reduction of quinones that results in the production of radical species. NQO1 functions as an important part of cellular antioxidant defense by detoxifying quinones thus preventing the formation of reactive oxygen species. Mutations in the gene for NQO1 have been associated with tardive dyskinesia (TD), an increased risk of hematotoxicity after exposure to benzene, and susceptibility to various forms of cancer. Altered expression of NQO1 has been seen in many tumors and is also associated with Alzheimer's disease (AD). NQO1 levels have been shown to be raised in may tumour types. This has led to a search for anti-tumour agents that can be activated by NQO1 resulting in specific targetting of these compounds to the tumour site. Many cytotoxic drugs contain the quinone moiety, such as the benzoquinone group, which can be activated by NQO1 through the reduction into hydroquinone [which in this case can auto-oxidize and lead to the formation of free radicals and alkylating species]. However, the rat enzyme has been shown to be significantly more effective in activating some of these compounds than the human and mouse enzymes. This indicates that the available cytotoxic drugs are better substrates for the rat enzyme and are not the most ideal prodrugs for activation by NQO1 in human tumors.
|
|
|
|
|
Database links
|
The links below go to external sites and will open in a new browser window
|
|
Raised in
|
Rabbit
|
|
Clonality
|
Polyclonal
|
|
Isotype
|
IgG
|
|
Purity
|
Whole antiserum
|
|
Storage buffer
|
Preservative: None Constituents: Whole serum
|
|
Form
|
Liquid
|
|
Concentration
|
Concentration not determined - why is this?
|
|
Storage instructions
|
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
|
| |
At Abcam, we have one centralized database to hold all of our product information, so that everything we know about this NQO1 antibody is on this datasheet. But please do contact us if you would like any reassurance! |
 |
|
| |
|
Search PubMed (MEDLINE) for references to NQO1
|
| |
NQO1 antibody - more information
|
Customer reviews (feedback) regarding NQO1 antibody |
Customer FAQs regarding NQO1 antibody |
Protocols for NQO1 antibody |
Price and availability of products related to NQO1 antibody |
| |
NQO1 antibody - related products:
|
|
|
| |
NQO1 antibody - other tools:
|
Contact Abcam with a Technical Enquiry about NQO1 antibody |
| |
All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"